Primary pulmonary salivary gland-type tumors in cytopathology practice: A systematic review and meta-analysis.

Cancer CytopatholSep 9, 2026

Henri Lagerstam, David Kalfert, Ivana Kholová

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness of cytologic diagnoses of primary pulmonary salivary gland-type tumors (PSGTs) in 106 patients across 49 studies. The study found a cytohistologic concordance of 48.1%, with fine-needle aspiration showing the highest sensitivity at 75.0%, indicating its potential for improved preoperative assessment.

Key findings

  • Cytohistologic concordance was 48.1% across the studies reviewed.
  • Fine-needle aspiration had the highest sensitivity at 75.0%.
  • Adenoid cystic carcinoma was the most common subtype, with 67 cases identified.
  • Bronchial brushing and washing had lower sensitivities of 34.2% and 38.1%, respectively.

Why it matters

Understanding the diagnostic challenges and effectiveness of cytologic techniques for PSGTs is crucial for clinicians, as accurate preoperative assessment can significantly impact treatment planning and patient outcomes.

Source

Published in Cancer Cytopathol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pathology (Anatomic & Clinical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.